MXPA05009849A - Combined therapy comprising nemorubicin and a cyclooxygenase-2-inhibitor. - Google Patents

Combined therapy comprising nemorubicin and a cyclooxygenase-2-inhibitor.

Info

Publication number
MXPA05009849A
MXPA05009849A MXPA05009849A MXPA05009849A MXPA05009849A MX PA05009849 A MXPA05009849 A MX PA05009849A MX PA05009849 A MXPA05009849 A MX PA05009849A MX PA05009849 A MXPA05009849 A MX PA05009849A MX PA05009849 A MXPA05009849 A MX PA05009849A
Authority
MX
Mexico
Prior art keywords
inhibitor
nemorubicin
cyclooxygenase
combined therapy
cox
Prior art date
Application number
MXPA05009849A
Other languages
Spanish (es)
Inventor
Antonino Suarato
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of MXPA05009849A publication Critical patent/MXPA05009849A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present Invention relates to the use of a morpholinyl anthracycline derivative, a pharmaceutically acceptable salt or a metabolite thereof, for the preparation of a medicament In combination with a Cox-2 Inhibitor for simultaneous, separate or sequential use for the treatment of cancer and to compositions or packaged units comprising a morpholinyl anthracycline derivative and a Cox-2 Inhibitor.
MXPA05009849A 2003-03-18 2004-03-04 Combined therapy comprising nemorubicin and a cyclooxygenase-2-inhibitor. MXPA05009849A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03075780 2003-03-18
PCT/EP2004/050251 WO2004082689A1 (en) 2003-03-18 2004-03-04 Combined therapy comprising nemorubicin and a cyclooxygenase-2-inhibitor

Publications (1)

Publication Number Publication Date
MXPA05009849A true MXPA05009849A (en) 2005-12-06

Family

ID=33016930

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05009849A MXPA05009849A (en) 2003-03-18 2004-03-04 Combined therapy comprising nemorubicin and a cyclooxygenase-2-inhibitor.

Country Status (6)

Country Link
EP (1) EP1605951A1 (en)
AU (1) AU2004222527A1 (en)
BR (1) BRPI0408518A (en)
CA (1) CA2519310A1 (en)
MX (1) MXPA05009849A (en)
WO (1) WO2004082689A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2547552T3 (en) 2008-02-01 2015-10-07 Genentech, Inc. Nemorubicin metabolite and similar reagents, antibody-drug conjugates and methods
BRPI0911647A2 (en) 2008-04-11 2015-10-13 Tianjin Hemay Bio Tech Co Ltd compounds with high activity anthracycline antibiotics, preparation methods and their use.
CA2721140C (en) * 2008-04-11 2016-02-09 Tianjin Hemay Bio-Tech Co. Ltd. Tetracyclic anthraquinone antibiotic derivatives with high activity, process for preparing the same and use thereof
RU2523419C2 (en) 2008-07-15 2014-07-20 Дженетек, Инк. Anthracycline derivative conjugates, methods for producing and using them as antitumour compounds
RU2563638C2 (en) 2010-12-02 2015-09-20 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Method of obtaining morpholinylanthracycline derivatives
US10149913B2 (en) 2014-09-12 2018-12-11 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
EP3200765A4 (en) * 2014-10-03 2018-05-30 EnGeneIC Molecular Delivery Pty Ltd Enhanced loading of intact, bacterially derived vesicles with small molecule compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0434960T3 (en) * 1989-12-19 1996-10-14 Pharmacia Spa Chiral 1,5-diiodo-2-methoxy or benzyloxy intermediates
GB2296495B (en) * 1994-12-23 1998-04-15 Erba Carlo Spa Anthracycline derivatives
CN1346282A (en) * 1998-12-23 2002-04-24 G.D.西尔公司 Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as combination therapy method in treating neoplasia
GB9909925D0 (en) * 1999-04-29 1999-06-30 Pharmacia & Upjohn Spa Combined preparations comprising anthracycline derivatives

Also Published As

Publication number Publication date
CA2519310A1 (en) 2004-09-30
AU2004222527A1 (en) 2004-09-30
BRPI0408518A (en) 2006-03-07
WO2004082689A1 (en) 2004-09-30
EP1605951A1 (en) 2005-12-21

Similar Documents

Publication Publication Date Title
AU2018256546A1 (en) Combination therapy with peptide epoxyketones
WO2006050155A3 (en) Cancer therapeutic compositions
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
HK1080447B (en) Retinol derivatives, their use in the treatment of cancer and for potentiating the efficacy of other cytotoxic agents
MXPA05011208A (en) Topical formulation of ivermectin for the treatment of dermatological conditions.
UA92000C2 (en) 1-benzylindole-2-carboxamide derivatives
MY142019A (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
MXPA05004919A (en) Pharmaceutical composition comprising a cdk inhibitor and gemcitabine.
WO2007058990A3 (en) Therapy using cytokine inhibitors
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
UA93709C2 (en) 12-imidazolyl-1-dodecanol and use thereof in the preparation of pharmaceutical compositions
IL178939A (en) Dual and triple combinations suitable for the synergistic treatment of breast cancer, pharmaceutical compositions comprising them and use thereof in the manufacture of medicaments or as medicaments for the treatment of breast cancer
TW200633700A (en) Methods of using temozolomide formulation intrathecally in the treatment of cancers
MX2009011900A (en) Diabetic wound healing.
DE60336225D1 (en) NEW PHARMACEUTICAL COMPOSITIONS, FLIBERSERINE POLYMORPH A CONTAINING
WO2005082413A3 (en) Ciclesonide and glycopyrronium combination
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
EP1503748A4 (en) Drugs for mitigating taxane-induced neurotoxicity
MXPA05009849A (en) Combined therapy comprising nemorubicin and a cyclooxygenase-2-inhibitor.
WO2006032525A3 (en) Combinational therapy for treating cancer
GB0328180D0 (en) Combination
GB0507598D0 (en) Composition
AR036321A1 (en) METHOD AND PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF LATE APPEARANCE DYSCINESIA.
YU57803A (en) Use of il-18 inhibitors for the treatment and/or prevention of heart disease
WO2007128588A3 (en) Glutadon